Alpha-lipoic acid as a new treatment option for Alzheimer's disease--a 48 months follow-up analysis. (Q42636363)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17982894%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

title

Alpha-lipoic acid as a new treatment option for Alzheimer's disease--a 48 months follow-up analysis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17982894%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

0 references

K Hager

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17982894%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

M Kenklies

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17982894%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

J McAfoose

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17982894%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

J Engel

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17982894%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

G Münch

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17982894%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

publication date

1 January 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17982894%20AND%20SRC:MED&resulttype=core&format=json

Journal of neural transmission. Supplementum

9 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17982894%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

page(s)

189-193

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17982894%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

issue

72

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17982894%20AND%20SRC:MED&resulttype=core&format=json

Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.

9 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_24

The pharmacology of the antioxidant lipoic acid

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_24

Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_24

Measuring cognitive change in a cohort of patients with Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_24

Oxidative stress: free radical production in neural degeneration.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_24

Alpha-lipoic acid as a new treatment option for Alzheimer [corrected] type dementia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_24

Tracking cognitive decline in Alzheimer's disease using the mini-mental state examination: a meta-analysis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_24

Individual trajectories of cognitive decline in patients with dementia of the Alzheimer type

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_24

Lipoic acid as a novel treatment for Alzheimer's disease and related dementias.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_24

Alzheimer's disease--synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_24

alpha-Lipoic acid as a biological antioxidant

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_24

Reactive Oxygen Species Mediate Cellular Damage in Alzheimer Disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_24

Rate of progression differs in frontotemporal dementia and Alzheimer disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_24

A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_24

Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_24

A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_24

Anti-inflammatory antioxidants attenuate the expression of inducible nitric oxide synthase mediated by advanced glycation endproducts in murine microglia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-73574-9_24

10.1007/978-3-211-73574-9_24

31 March 2020

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17982894%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

1 reference